HIV infection is associated with a high risk of non-Hodgkin lymphoma (NHL), especially Burkitt's lymphoma (BL), which represents 10%–35% of HIV-associated NHL. The incidence of NHL has tended to decrease in the combined antiretroviral therapy (cART) era. This is not true for BL, for which the incidence appears to have been stable. Patients with BL present peculiar characteristics with higher CD4 counts, higher viral load and more recent HIV infection than other NHLs [
- Hernández-Ramírez R.U.
- Qin L.
- Lin H.
- Leyden W.
- Neugebauer R.S.
- Althoff K.N.
- et al.
Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.
Lancet HIV. 2019; 6: e240-e249https://doi.org/10.1016/S2352-3018(18)30360-6
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.Lancet HIV. 2019; 6: e240-e249https://doi.org/10.1016/S2352-3018(18)30360-6
- Amc 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.Blood. 2015; 126: 160-166https://doi.org/10.1182/blood-2015-01-623900
- Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.Leuk Lymphoma. 2014; 55: 2341-2348https://doi.org/10.3109/10428194.2013.878933
- Risk-Adapted therapy IN adults with burkitt lymphoma: updated results of a multicenter prospective phase ii study of DA-EPOCH-R.Hematol Oncol. 2017; 35: 133-134https://doi.org/10.1002/hon.2437_122
- Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).Ann Hematol. 2014; 93: 177-178https://doi.org/10.1007/s00277-013-1771-8
- Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.Lancet. 2016; 387: 2402-2411https://doi.org/10.1016/S0140-6736(15)01317-3
- Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.AIDS. 2017; 31: 2493-2501https://doi.org/10.1097/QAD.0000000000001652
- High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 Lymphovir cohort.Clin Infect Dis. 2015; 61: 1469-1475https://doi.org/10.1093/cid/civ627
- Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort.Br J Haematol. 2015; 168: 806-810https://doi.org/10.1111/bjh.13221
- Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.Haematologica. 2018; 103: 857-864https://doi.org/10.3324/haematol.2017.180893
Published online: September 05, 2020
Accepted: July 30, 2020
Received in revised form: July 24, 2020
Received: April 15, 2020
© 2020 Elsevier Ltd. All rights reserved.